News releases
12 March 2025
New data highlight the positive impact of Exact Sciences’ Oncotype DX® test on patient care and healthcare efficiency
2022
7 December 2022
Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022
28 April 2022
Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients
2021
8 December 2021
New Data Presented at SABCS 2021 Strengthen Value of Oncotype DX Breast Recurrence Score® Test to Inform Clinical Decision-making
1 December 2021
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
20 May 2021
New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer
24 March 2021
New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score® as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer
2020
9 December 2020
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
2 October 2020
New Real-World Evidence Further Demonstrates the Clinical Utility of the Oncotype DX Breast Recurrence Score® Test, Beyond Clinical Risk Factors, in Guiding Chemotherapy Treatment Decisions in Patients with Early-stage Breast Cancer
29 May 2020
New Data and Society Guidelines Support Value of Oncotype DX Breast Recurrence Score® Test in Guiding Neoadjuvant Treatment Decisions for Newly Diagnosed Patients
14 May 2020
New Oncotype DX Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results
2019
12 December 2019
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer
30 September 2019
New TAILORx Data, Published in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy Treatment
21 August 2019
New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy for Node-Negative and Node-Positive Early-Stage Breast Cancer
21 June 2019
German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score Test
4 June 2019
Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
3 June 2019
Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score Test in Node-negative Breast Cancer
25 March 2019
New Long-Term Outcomes Data Reconfirm Value of Oncotype DX Breast Recurrence Score Test to Target Chemotherapy
Get in touch
